Reuters logo
Eye drug firm Akorn to buy rival Hi-Tech Pharmacal for $640 mln
August 27, 2013 / 11:19 AM / 4 years ago

Eye drug firm Akorn to buy rival Hi-Tech Pharmacal for $640 mln

Aug 27 (Reuters) - Specialty pharmaceutical company Akorn Inc will buy rival Hi-Tech Pharmacal Co Inc for $640 million in cash to expand its eye drug portfolio to other dosage forms such as oral liquids, topical creams and ointments.

Akorn will pay $43.50 per Hi-Tech share, representing a premium of 23.5 percent to Hi-Tech’s last close.

The deal will make Akorn the third-largest U.S. generic ophthalmic player and will significantly increase its retail presence in both prescription and over-the-counter products, the companies said in a statement.

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below